Correlation of in-vitro activity and pharmacokinetic parameters with in-vivo effect of amoxycillin, co-amoxiclav and cefotaxime in a murine model of pneumococcal pneumonia

Journal of Antimicrobial Chemotherapy

Volumn 38, Issue 2, 1996, Pages 227-236

  Soriano, F ^a   Ponte, C ^a   Nieto, E ^a   Parra, A ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFOTAXIME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; LOBAR PNEUMONIA; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; STRAIN DIFFERENCE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029768086     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/38.2.227     Document Type: Article

References (17)

1. Andes, D., Urban, A. & Craig, W. A. (1995). In-vivo activity of amoxicillin (AMOX) and amoxicillin/clavulanate (AMOX/CLAV) against penicillin-resistant pneumococci. In Program and Abstracts of the Thirty-Fifth Interscience Conference Antimicrobial Agents and Chemotherapy, San Francisco, 1995. Abstract A82, p. 16. American Society for Microbiology, Washington, DC.
2. Austriam, R. & Gold, J. (1964). Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Annals of Internal Medicine 60, 759-76.
3. Azoulay-Dupuis, E., Vallee, E., Veber, B., Bedos, J. P., Bauchet, J. & Pocidalo, J. J. (1992). In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia. Antimicrobial Agents and Chemotherapy 36, 2698-703.
4. Bakker-Woudenberg, I. A. J. M. & Roosendaal, R. (1988). Impact of dosage regimens on the efficacy of antibiotics in the immunocompromised host. Journal of Antimicrobial Chemotherapy 21, 145-7.
5. Barry, B., Muffat-Joly, M., Gehanno, P. & Pocidalo, J. J. (1993). Effect of increased dosages of amoxicillin in treatment of experimental middle ear otitis due to penicillin-resistant Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 37, 1599-603.
6. Beale, A. S., Gisby, J. & Sutherland, R. (1988). Efficacy of amoxycillin/clavulanic acid in experimental Bacteroides fragilis/Escherichia coli mixed infections. Journal of Antimicrobial Chemotherapy 21, 451-9.
7. Fernández-Guerrero, M. L., Arbol, F., Verdejo, C., Fernández-Roblas, R. & Soriano, F. (1994). Treatment of experimental endocarditis due to penicillin-resistant Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 38, 1103-6.
8. Gisby, J., Wightman, B. J. & Beale, A. S. (1991). Comparative efficacies of ciprofloxacin, amoxicillin, amoxicillin-clavulanic acid, and cefaclor against experimental Streptococcus pneumoniae respiratory infections in mice. Antimicrobial Agents and Chemotherapy 35, 831-6.
9. Klugman, K. P. (1994). Management of antibiotic-resistant pneumococcal infections. Journal of Antimicrobial Chemotherapy 34, 191-3.
10. Kramer, M. R., Rudensky, B., Hadas-Halperin, I., Isacsohn, M. & Melzer, E. (1987). Pneumococcal bacteremia- no change in mortality in 30 years: analysis of 104 cases and review of the literature. Israel Journal of Medical Sciences 23, 174-80.
11. Moine, P., Vallée, E., Azoulay-Dupuis, E., Bourget, P., Bédos, J. P., Bauchet, J. et al. (1994). In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrobial Agents and Chemotherapy 38, 1953-8.
12. National Committee for Clinical Laboratory Standards. (1993). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard M7-A3. NCCLS, Villanova, PA.
13. Nava, J. M., Bella, F., Garau, J., Lite, J., Morera, M. A., Marti, C. et al. (1994). Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study. Clinical Infectious Disease 19, 884-90.
14. Pallarés, R., Gudiol, F., Liñares, J., Ariza, J., Rufi, G., Murgui, L. et al. (1987). Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. New England Journal Medicine 317, 18-22.
15. Pallarés, R., Liñares, J., Vadillo, M., Cabellos, C., Manresa, F., Viladrich, P. et al. (1995). Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. New England Journal Medicine 333, 474-80.
16. Sánchez, C., Armengol, R., Lite, J., Mir, I. & Garau, J. (1992). Penicillin-resistant pneumococci and community-acquired pneumonia. Lancet 333, 988.
17. Watanakakunakorn, C., Greifenstein, A., Stroh, K., Jarjoura, D. G., Blend, D., Cugino, A. et al. (1993). Pneumococcal bacteremia in three community teaching hospitals from 1980 to 1989. Chest 103, 1152-6.